|
|
 |
|
Viewing report
|
|
|
|
Becton-Dickinson Medical Device Company Intelligence Report
Espicom Business Intelligence Ltd, May 2011, Pages: 50
Becton, Dickinson and Company (BD) is engaged principally in the manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences.
BD Medical produces a portfolio of medical devices that are used in a wide range of healthcare settings. They include safety-engineered injection, infusion and surgery products. BD Medical’s principal product lines include needles, syringes and intravenous (IV) catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self injection of insulin and other drugs used in the treatment of diabetes; prefillable drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; regional anaesthesia needles and trays; sharps disposal containers; and home healthcare products. The primary markets served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; public health agencies; pharmaceutical companies; and healthcare workers.
BD Diagnostics provides products for the collection and transport of diagnostic specimens and instrumentation for analysis across a broad range of infectious disease testing, including healthcare-associated infections (HAIs). BD Diagnostics’ principal products and services include integrated systems for specimen collection; safety-engineered collection products and systems; plated media; automated blood culturing systems; molecular testing systems for sexually-transmitted diseases and HAIs; micro-organism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screenings; and rapid diagnostic assays. BD Diagnostics serves hospitals, laboratories and clinics; reference laboratories; blood banks; healthcare workers; patients; physicians’ office practices; and industrial microbiology laboratories.
BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. BD Biosciences’ principal product lines include fluorescence activated cell sorters and analysers; cell imaging systems, monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; tools to aid in drug discovery and growth of tissue and cells; cell culture media supplements for biopharmaceutical manufacturing; and diagnostic assays. The primary markets served by BD Biosciences are research and clinical laboratories; hospitals and transplant centres; blood banks; and biotechnology and pharmaceutical companies.
BD’s products are manufactured and sold worldwide. The company has manufacturing operations outside the US in Brazil, Canada, China, France, Germany, Hungary, India, Ireland, Japan, Mexico, Pakistan, Singapore, South Korea, Spain, Sweden and the UK.
In the fiscal year ended 30th September 2010, BD generated net earnings of US$1.32 billion on revenues of US$7.37 billion. In the first six months of fiscal 2011 (ended 31st March 2011), the company produced earnings of US$628 million on revenues of US$3.76 billion. BD has a global workforce of approximately 28,800 employees.
This company report provides
Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format
Financial Review
Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location
Strategic Focus
Investigates the company’s aims and its areas of focus
Products
Core product areas, key brands, product approvals and launches Research and Development
How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?
Manufacturing and Distribution
Identifying the company’s manufacturing locations
Sales and marketing facilities
Agreements
With whom has the company reached agreements and what do they involve?
Key contracts awarded
Mergers, Acquisitions, Minority Investments and Divestments
Litigation
Key Corporate Events
The report was produced as part of Medical Device Companies Analysis (MDCA). For more information on MDCA, click here.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Molecular Diagnostics - Global Strategic Business Report
Point of Care Testing: Evaluating the Return to Evidence Based Medicine, Novel Technologies and the Competitive Landscape
Point of Care Diagnostic Testing World Markets
Point of Care Diagnostic Testing Sector Trends
Clinical Diagnostics Automation - Global Strategic Business Report
The Top 100 Point-Of-Care Manufacturing Companies Worldwide (2nd Edition)
Cell-Based Assays - Global Strategic Business Report
Blood Processing Supplies And Equipment - Global Strategic Business Report
Blood Banking and Blood Products - Global Strategic Business Report
Diabetes Diagnostics - Global Strategic Business Report
|
|
|
|
